Amicus Therapeutics, Inc.

NasdaqGM:FOLD 주식 보고서

시가총액: US$2.8b

Amicus Therapeutics 관리

관리 기준 확인 4/4

Amicus Therapeutics CEO는 Brad Campbell, Jan2015 에 임명되었습니다 의 임기는 9.83 년입니다. 총 연간 보상은 $ 8.20M, 8.5% 로 구성됩니다. 8.5% 급여 및 91.5% 보너스(회사 주식 및 옵션 포함). 는 $ 8.44M 가치에 해당하는 회사 주식의 0.3% 직접 소유합니다. 8.44M. 경영진과 이사회의 평균 재임 기간은 각각 7.7 년과 6.3 년입니다.

주요 정보

Brad Campbell

최고 경영자

US$8.2m

총 보상

CEO 급여 비율8.5%
CEO 임기9.8yrs
CEO 소유권0.3%
경영진 평균 재임 기간7.7yrs
이사회 평균 재임 기간6.3yrs

최근 관리 업데이트

Recent updates

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Nov 10
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 18

'Boring' Amicus Therapeutics Is Making Progress

Sep 29

Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector

Aug 16

Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Jul 02
Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Feb 29

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Dec 19
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Jul 06
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23
Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06
We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25
Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

CEO 보상 분석

Brad Campbell 의 보수는 Amicus Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$105m

Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$8mUS$699k

-US$152m

Sep 30 2023n/an/a

-US$174m

Jun 30 2023n/an/a

-US$185m

Mar 31 2023n/an/a

-US$204m

Dec 31 2022US$9mUS$591k

-US$237m

Sep 30 2022n/an/a

-US$264m

Jun 30 2022n/an/a

-US$281m

Mar 31 2022n/an/a

-US$270m

Dec 31 2021US$5mUS$551k

-US$250m

Sep 30 2021n/an/a

-US$239m

Jun 30 2021n/an/a

-US$252m

Mar 31 2021n/an/a

-US$254m

Dec 31 2020US$5mUS$516k

-US$277m

Sep 30 2020n/an/a

-US$295m

Jun 30 2020n/an/a

-US$293m

Mar 31 2020n/an/a

-US$325m

Dec 31 2019US$4mUS$501k

-US$356m

Sep 30 2019n/an/a

-US$345m

Jun 30 2019n/an/a

-US$442m

Mar 31 2019n/an/a

-US$419m

Dec 31 2018US$3mUS$468k

-US$349m

Sep 30 2018n/an/a

-US$340m

Jun 30 2018n/an/a

-US$293m

Mar 31 2018n/an/a

-US$279m

Dec 31 2017US$2mUS$450k

-US$284m

보상 대 시장: Brad 의 총 보상 ($USD 8.20M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.63M ).

보상과 수익: Brad 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Brad Campbell (48 yo)

9.8yrs

테뉴어

US$8,202,366

보상

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...

리더십 팀

이름위치테뉴어보상소유권
Bradley Campbell
CEO, President & Director9.8yrsUS$8.20m0.30%
$ 8.4m
Simon Nicolas Harford
Chief Financial Officer1.3yrsUS$3.27m0.0048%
$ 135.4k
Ellen Rosenberg
Chief Legal Officer & Corporate Secretary8.8yrsUS$4.08m0.064%
$ 1.8m
David Clark
Chief People Officer6.1yrsUS$3.21m0.046%
$ 1.3m
Jeffrey Castelli
Chief Development Officerno dataUS$3.67m0.080%
$ 2.3m
Samantha Prout
Chief Accounting Officer & Controller6.7yrs데이터 없음0.025%
$ 703.8k
Jill Weimer
Chief Science Officerno data데이터 없음데이터 없음
Andrew Faughnan
Senior Director of Investor Relationsno data데이터 없음데이터 없음
Patrik Florencio
Global Chief Compliance & Risk Officer9.3yrs데이터 없음데이터 없음
Diana Moore
Head of Global Corporate Communicationsno data데이터 없음데이터 없음
Jayne Gershkowitz
Chief Patient Advocate9.2yrs데이터 없음데이터 없음
Julie Yu
Chief Program Officer4.5yrs데이터 없음데이터 없음

7.7yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: FOLD 의 관리팀은 노련하고 경험 (평균 재직 기간 7.7 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Bradley Campbell
CEO, President & Director6.4yrsUS$8.20m0.30%
$ 8.4m
Burke Whitman
Independent Director5.4yrsUS$391.25k0.026%
$ 740.2k
Michael Kelly
Independent Director3.9yrsUS$391.25k0.0098%
$ 279.9k
Glenn Sblendorio
Independent Director18.4yrsUS$407.07k0.025%
$ 714.0k
Margaret McGlynn
Independent Director15.1yrsUS$401.25k0.017%
$ 482.7k
Michael Raab
Chairman & Lead Independent Director20.8yrsUS$426.25k0.025%
$ 714.0k
Eiry Roberts
Independent Director3.4yrsUS$390.00k0.0080%
$ 229.0k
Lynn Bleil
Independent Director6.2yrsUS$397.50k0.024%
$ 695.8k

6.3yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: FOLD 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.